Literature DB >> 22691258

Patients with oral allergic syndrome to apple have intense proliferative response to BET V 1.

G Ciprandi1, G Fenoglio, F Kalli, M De Amici, S Leonardi, M Miraglia Del Giudice, C Salpietro, M La Rosa, S Caimmi, G L Marseglia.   

Abstract

Patients with pollen allergy may frequently present an additional food-related allergy (Oral Allergic Syndrome, OAS), as consequence of cross-reactivity between pollen allergens (mainly birch, hazelnut, alder, mugwort) and vegetable allergens. The aim of this study was to evaluate the effect on Bet v 1-induced T cell proliferation exerted by the presence of OAS in birch patients. Fourteen allergic patients were evaluated (6 males, mean age 35.8 years). All of them were monosensitized to birch and suffered from allergic rhinitis: 4 had also OAS to apple. Proliferation of peripheral mononuclear cells was evaluated using Bet v 1 and non-specific stimuli. OAS had higher proliferation than non-OAS patients. In addition, there were significant relationships between immunological and clinical parameters in OAS patients. This study evidences that OAS characterizes a more severe form of birch allergy: as OAS patients had higher SI, circulating eosinophils, and IgE levels. Thus, this study confirms the previous report and underlines the relevance of measuring recombinant birch allergen as higher values may suggest a reliable prediction of OAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691258

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  2 in total

1.  Cross-reactivity between aeroallergens and food allergens.

Authors:  Florin-Dan Popescu
Journal:  World J Methodol       Date:  2015-06-26

2.  Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.

Authors:  Felix Husslik; Kay-Martin Hanschmann; Ariane Krämer; Christian Seutter von Loetzen; Kristian Schweimer; Iris Bellinghausen; Regina Treudler; Jan C Simon; Lothar Vogel; Elke Völker; Stefanie Randow; Andreas Reuter; Paul Rösch; Stefan Vieths; Thomas Holzhauser; Dirk Schiller
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.